
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZNF638 (zinc finger protein 638) encodes a nucleoplasmic protein that binds cytidine-rich sequences in double-stranded DNA. The protein contains MH1, MH2, and MH3 domains and is associated with the packaging, transfer, or processing of transcripts. These features suggest a role in coordinating DNA-associated and RNA-related cellular processes within the nucleus.
5637 is a human bladder carcinoma cell line established from a primary bladder tumor of a 68-year-old male patient. The cells are known to produce multiple growth factors, including stem cell factor (SCF), interleukins, and colony-stimulating factors. 5637 cells are used as a model for studying bladder cancer biology, tumor-associated signaling, and growth factor regulation.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_014497
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?